SCHEMBL5457915

SCHEMBL5457915

COCCNc1nc(N)c2nc(O)n(Cc3cccc(CC(=O)O)c3)c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 10/20 0.45
TMIGD3 P0DMS9 4/20 0.41
ADORA2A P29274 4/20 0.41
ADORA2B P29275 4/20 0.41
ADORA1 P30542 4/20 0.41
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PCSK9 Q8NBP7 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5471545 0.93 TLR7 (0.53) TLR7TMIGD3ADORA2AADORA2BADORA1
SCHEMBL2060539 0.88 TLR7 (0.52) TLR7TMIGD3ADORA2AADORA2BADORA1
SCHEMBL7209381 0.88 TLR7 (0.52) TLR7TMIGD3ADORA2AADORA2BADORA1
SCHEMBL15695431 0.86 TLR7 (0.45) TLR7TMIGD3ADORA2AADORA2BADORA1
SCHEMBL5471380 0.83 TLR7 (0.49) TLR7TMIGD3ADORA2AADORA2BADORA1
SCHEMBL2060343 0.83 TLR7 (0.59) TLR7
SCHEMBL2060059 0.83 TLR7 (0.53) TLR7TMIGD3ADORA2AADORA2BADORA1
SCHEMBL5471534 0.83 TLR7 (0.52) TLR7TMIGD3ADORA2AADORA2BADORA1
SCHEMBL5464911 0.82 TLR7 (0.41) TLR7KDM4EALDH1A1GLAGAA
SCHEMBL10309736 0.80 TLR7 (0.44) TLR7KDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225303-A1 8-Oxoadenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-09-27 US claimed
EP-1728792-A1 8-OXOADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-06 EP claimed
US-20070225303-A1 8-Oxoadenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-09-27 US disclosed
US-20070225303-A1 8-Oxoadenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-09-27 US disclosed
US-20070225303-A1 8-Oxoadenine Compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-09-27 US disclosed
EP-1728792-A1 8-OXOADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225303-A1 8-Oxoadenine Compound TLR7, CCR8, TLR8 TLR7 1/4885TMIGD3 3548/4885ADORA2A 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.